Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Phase I/II results support further development of Leuvectin

Oct. 8, 1999

NCI supports clinical development of StressGen's lead product

Oct. 7, 1999

York Medical to commence phase I/II trial of head and neck cancer therapy

Sep. 30, 1999

ImmunoGen exercises put option

Sep. 30, 1999

StressGen completes phase I trial of HspE7

Sep. 28, 1999

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Sep. 21, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...